Business
Currency:USD
2024/Q1
Stock NameRevenueRatio
BRUKINSA®488.52M64.99%
Tislelizumab145.28M19.33%
XGEVA®43.38M5.77%
POBEVCY®16.63M2.21%
BLINCYTO®14.37M1.91%
KYPROLIS®14.11M1.88%
Other product12.4M1.65%
REVLIMID®12.23M1.63%
Other4.73M0.63%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S.1.13B45.89%
China1.1B44.82%
Rest of world202.01M8.22%
Europe26.6M1.08%
